• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by iRhythm Technologies Inc.

    11/13/25 2:34:17 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    iRhythm Technologies, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    450056106

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    450056106


    1Names of Reporting Persons

    SANDS CAPITAL MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,468,245.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    2,236,110.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,236,110.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.9 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 32,219,143 Shares outstanding as of October 23, 2025 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on October 30, 2025).


    SCHEDULE 13G

    CUSIP No.
    450056106


    1Names of Reporting Persons

    SANDS FRANK M.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    1,468,245.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    2,236,110.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,236,110.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.9 %
    12Type of Reporting Person (See Instructions)

    IN, HC

    Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 32,219,143 Shares outstanding as of October 23, 2025 (according to the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on October 30, 2025).


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    iRhythm Technologies, Inc.
    (b)Address of issuer's principal executive offices:

    699 8TH STREET, 699 8TH STREET, San Francisco, CALIFORNIA, 94103.
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed jointly by Sands Capital Management, LLC ("SCM") and Frank M. Sands ("Sands"). Sands holds ultimate voting and investment power over securities held by SCM.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of SCM and Sands is 1000 Wilson Blvd., Suite 3000, Arlington, VA 22209.
    (c)Citizenship:

    SCM is organized under the laws of the State of Delaware. Sands is a citizen of the United States.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    450056106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See rows 5 through 11 of cover pages.
    (b)Percent of class:

    See rows 5 through 11 of cover pages.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See rows 5 through 11 of cover pages.

     (ii) Shared power to vote or to direct the vote:

    See rows 5 through 11 of cover pages.

     (iii) Sole power to dispose or to direct the disposition of:

    See rows 5 through 11 of cover pages.

     (iv) Shared power to dispose or to direct the disposition of:

    See rows 5 through 11 of cover pages.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Securities reported on this Schedule 13G are held in the accounts of various clients of SCM, which may include pension plans, endowments, foundations, mutual funds, charities, state and municipal government entities, Taft-Hartley plans, families, and individuals, among other types. Such clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No such client's interest in the class of securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    SCM is reporting hereunder as an investment adviser pursuant to Item 3(e) above. Sands is reporting hereunder as a control person pursuant to Item 3(g) above.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    SANDS CAPITAL MANAGEMENT, LLC
     
    Signature:/s/ Alexandra R. Fulk
    Name/Title:Alexandra R. Fulk, Chief Compliance Officer, Senior Counsel
    Date:11/13/2025
     
    SANDS FRANK M.
     
    Signature:/s/ Frank M. Sands
    Name/Title:Frank M. Sands
    Date:11/13/2025
    Get the next $IRTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRTC

    DatePrice TargetRatingAnalyst
    9/23/2025$185.00In-line
    Evercore ISI
    8/20/2025$200.00Buy
    BofA Securities
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    12/3/2024$86.00Equal Weight
    Wells Fargo
    10/4/2024$78.00Neutral
    Goldman
    6/20/2024$115.00Peer Perform → Outperform
    Wolfe Research
    12/11/2023$110.00Neutral → Buy
    Citigroup
    7/19/2023$130.00Outperform
    Robert W. Baird
    More analyst ratings

    $IRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm's Zio Long-Term Continuous Monitoring in an Asian Population

    iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions.Large-scale analysis of more than 400,000 patients1 supports the consistency and generalizability of Zio long-term ECG monitoring (LTCM) performance across populations; median wear and analyzable time among patients identified as Asian (3.4% of the cohort) were comparable to those of non-Asian patients, and findings were consistent with Zio LTCM performance previously reported in the published CAMELOT2 and AVALON3 studies. SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced new dat

    11/21/25 8:10:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025

    Real-world data across more than 1 million patients published in Heart Rhythm show that 24–48-hour monitoring can miss actionable arrhythmias and highlights the value of iRhythm's Zio® long-term continuous monitoring (LTCM)– even in patients with frequent (i.e., daily) symptoms1Data from more than 742,000 patients presented at the American Heart Association (AHA) Scientific Sessions 2025 confirm that at-home self-application and activation of Zio 14-day patch-based LTCM devices achieve high compliance, strong engagement, and data quality comparable to in-clinic application2Additional large-scale real-world analyses also presented at AHA 2025 provide expanded insights into CKM/CKD risk and re

    11/11/25 8:05:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies to Participate in Upcoming Investor Conferences

    SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. Wolfe Research 2025 Healthcare Conference on Tuesday, November 18, 2025, at 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time)Jefferies 2025 Global Healthcare Conference on Thursday, November 20, 2025, at 9:30 a.m. Greenwich Mean Time (1:30 a.m. Pacific Time)Citi 2025 Global Healthcare Conference on Wednesday, December 03, 2025, at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time)Ever

    11/4/25 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on iRhythm with a new price target

    Evercore ISI initiated coverage of iRhythm with a rating of In-line and set a new price target of $185.00

    9/23/25 8:17:27 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    BofA Securities initiated coverage on iRhythm with a new price target

    BofA Securities initiated coverage of iRhythm with a rating of Buy and set a new price target of $200.00

    8/20/25 8:56:18 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00

    5/2/25 8:03:46 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by iRhythm Technologies Inc.

    SCHEDULE 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/13/25 2:34:17 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - iRhythm Technologies, Inc. (0001388658) (Filer)

    11/12/25 5:17:38 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by iRhythm Technologies Inc.

    144 - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/10/25 4:02:46 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Talwalkar Abhijit Y exercised 5,312 shares at a strike of $10.71 and sold $924,962 worth of shares (5,312 units at $174.13) (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/12/25 4:33:59 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    President and CEO Blackford Quentin S. sold $2,571,907 worth of shares (14,059 units at $182.94), decreasing direct ownership by 8% to 164,979 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/4/25 5:04:10 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Wilson Daniel G. sold $1,659,520 worth of shares (8,000 units at $207.44), decreasing direct ownership by 23% to 26,470 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/3/25 4:30:36 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/5/24 11:59:44 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    8/5/24 5:35:18 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

    4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)

    12/6/23 7:08:38 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Leadership Updates

    Live Leadership Updates

    View All

    iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

    iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

    2/29/24 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Derrick Sung Joins Aerin Medical as Chief Financial Officer

    A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer

    11/20/23 9:00:00 AM ET
    $IRTC
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

    SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering

    6/6/23 9:00:39 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    Financials

    Live finance-specific insights

    View All

    $IRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    iRhythm Technologies Announces Third Quarter 2025 Financial Results

    SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $192.9 million, a 30.7% increase compared to third quarter 2024Gross margin of 71.1%, a 230-basis point increase compared to third quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $565.2 million as of September 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights

    10/30/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies to Report Third Quarter 2025 Financial Results on October 30, 2025

    SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, October 30, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leadin

    10/16/25 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces Second Quarter 2025 Financial Results

    SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA Recent Operational Highlights

    7/31/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 12:54:21 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 9:52:49 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/7/24 4:05:49 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care